In Brief: Fisher Scientific
This article was originally published in The Gray Sheet
Executive Summary
Fisher Scientific: Laboratory instrument firm is evaluating an unsolicited acquisition offer from Trinity I Fund L.P., an investment group associated with members of the Bass family of Texas, the company announces June 5. Trinity, a minority Fisher shareholder, made the offer at a June 4 meeting with Fisher's board of directors. Hampton, New Hampshire-based Fisher says it will respond to the proposal after reviewing it with financial advisors Lazard Freres and Salomon Brothers and legal advisors Wachtell, Lipton, Rosen & Katz. Fisher stock, which had fallen sharply in early May due to lower-than-expected first quarter results, rose 7-1/2 points on the news to close June 5 at 45-3/8. However, Standard & Poor's places its ratings for Fisher on "CreditWatch with negative implications," citing "the potential for weakened credit protection measures associated with an acquisition, including possible defensive tactics"...
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.